Skip to main content
Fig. 2 | Molecular Neurodegeneration

Fig. 2

From: The major TMEM106B dementia risk allele affects TMEM106B protein levels, fibril formation, and myelin lipid homeostasis in the ageing human hippocampus

Fig. 2

TMEM106B increases with age in the human brain. (A) Schematic of TMEM106B protein domains showing the unique peptide sequence used to identify and quantify TMEM106B protein levels in human hippocampus samples. (B) MS2 extracted ion chromatogram of the identified peptide (SAYVSYDVQKR) and (C) annotated MS2 fragmentation spectrum corresponding to the peak with retention time (RT) 11.28 min. (D) TMEM106B levels as a function of age in CA1 hippocampus samples from the NSW BTRC and QLD Brain Bank, (E,F) TMEM106B levels as a function of age in dorsolateral prefrontal cortex samples from the (E) Johns Hopkins Ageing (ages 30 to 68) and (F) Emory ADRC Brain Bank cohorts (ages 45 to 96). (G) Peptide-level associations of TMEM106B with age in the Emory ADRC Brain Bank cohort using peptides that map to the C-terminus (residues 130–139) (left) and the N-terminus (residues 15–27) (right). (H) TMEM106B mRNA levels as a function of age from GSE30272, using age ranges 0–78 (left), 30–60 (middle), and 60–80 (right)

Back to article page

Molecular Neurodegeneration

ISSN: 1750-1326